The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc.

Biotech stocks have performed well this year. The SPDR S&P Biotech ETF -- an industry benchmark -- is up 21% this year. Two ...

Amgen to present new data from cardiovascular portfolio, including late-breaking results from phase 3 VESALIUS-CV trial of Repatha at AHA scientific sessions: Thousand Oaks, Calif ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...

Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.